Literature DB >> 25646654

Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways.

Guangxiu Wang1, Fang Dai2, Kai Yu3, Zhifan Jia1, Anling Zhang1, Qiang Huang4, Chunsheng Kang1, Hao Jiang5, Peiyu Pu1.   

Abstract

Resveratrol (Res), a natural polyphenolic compound, has anticancer activity in a variety of cancers. In the present study, the antitumor effect and underlying molecular mechanism of Res on rat C6 glioma growth was studied. The results demonstrated that Res inhibited glioma cell proliferation, arrested cell cycle in S phase and induced apoptosis in vitro. Res also suppressed intracranial C6 tumor growth in vivo and prolonged survival in a fraction of the rats bearing intracranial gliomas. Res significantly downregulated the specific miRs, including miR-21, miR-30a-5p and miR-19, which have been identified as oncomiRs in our previous studies, and altered the expression of their targeting and crucial genes for glioma formation and progression such as p53, PTEN, EGFR, STAT3, COX-2, NF-κB and PI3K/AKT/mTOR pathway. Therefore, the anti-glioma effect of Res, at least in part, is through the regulation of oncogenic miRNAs. The effect of Res on non-coding RNAs should be studied further. Res is a potential multi-targeting drug for the treatment of gliomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25646654     DOI: 10.3892/ijo.2015.2863

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  26 in total

1.  PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.

Authors:  Lei Shi; Xifeng Fei; Zhimin Wang; Yongping You
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-07-14       Impact factor: 2.416

Review 2.  Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer.

Authors:  Shreena J Desai; Ben Prickril; Avraham Rasooly
Journal:  Nutr Cancer       Date:  2018-03-26       Impact factor: 2.900

Review 3.  C6 cell line: the gold standard in glioma research.

Authors:  D Giakoumettis; A Kritis; N Foroglou
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

4.  Resveratrol and siRNA in combination reduces Hsp27 expression and induces caspase-3 activity in human glioblastoma cells.

Authors:  Evren Önay Uçar; Aslıhan Şengelen
Journal:  Cell Stress Chaperones       Date:  2019-05-09       Impact factor: 3.667

5.  Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-κB signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.

Authors:  Kranthi Kiran Kishore T; Raghu Ganugula; Deepak Reddy Gade; Geereddy Bhanuprakash Reddy; Siddavaram Nagini
Journal:  Tumour Biol       Date:  2015-09-05

Review 6.  Therapeutic potentials of resveratrol in combination with radiotherapy and chemotherapy during glioblastoma treatment: a mechanistic review.

Authors:  AmirAhmad Arabzadeh; Tohid Mortezazadeh; Tayebeh Aryafar; Esmaeil Gharepapagh; Mehrsa Majdaeen; Bagher Farhood
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 5.722

7.  HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas.

Authors:  Yu Zhu; Xuebin Zhang; Lisha Qi; Ying Cai; Ping Yang; Geng Xuan; Yuan Jiang
Journal:  Oncotarget       Date:  2016-03-22

8.  Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets.

Authors:  Daeyong Jin; Hyunju Lee
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

9.  Development of PLGA-lipid nanoparticles with covalently conjugated indocyanine green as a versatile nanoplatform for tumor-targeted imaging and drug delivery.

Authors:  Yu Xin; Tie Liu; Chenlong Yang
Journal:  Int J Nanomedicine       Date:  2016-11-04

Review 10.  Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression.

Authors:  Edward A Ratovitski
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.